MULTivessel Immediate Versus STAged RevaScularization in Acute Myocardial Infarction -The MULTIST… (NCT03135275) | Clinical Trial Compass
CompletedNot Applicable
MULTivessel Immediate Versus STAged RevaScularization in Acute Myocardial Infarction -The MULTISTARS AMI Trial
Switzerland840 participantsStarted 2016-10
Plain-language summary
The primary objective of the trial is to compare, in patients presenting with ST segment elevation myocardial infarction (STEMI) and multi-vessel disease (MVD), the safety and efficacy of immediate complete revascularization of all significant coronary lesions versus culprit vessel only revascularization and staged percutaneous coronary intervention (PCI) of all significant coronary lesions (within 19 to 45 days), in a non-inferiority trial using a third generation, biodegradable-polymer, everolimus-eluting stent.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age ≥ 18 years
* Spontaneous acute STEMI (patients presenting within 24 hours of symptom onset)
* Suitability for PCI from femoral or radial access
* Coronary anatomy suitable for complete coronary revascularization with Synergy® stent implantation
* Identifiable culprit lesion/artery
* At least one non-culprit coronary stenosis ≥ 70% in at least two projections, in a vessel with a lumen diameter ≥2.25 - ≤5.75 mm, other than the culprit artery
* TIMI Flow 3 or TIMI flow 2 after revascularization of the culprit artery
* Stable hemodynamics at the end of the culprit vessel revascularization
Exclusion Criteria:
* Inability to give informed consent
* Cardiogenic shock
* Prolonged resuscitation \>10 min
* General unsuitability for PCI
* Need for emergency CABG
* Previous CABG
* Planned hybrid revascularization
* Coronary artery dissection
* STEMI due to ST
* Previous documented allergic reaction to everolimus or to any stent material
* Severe mechanical complication of acute myocardial infarction
* Pre-existing severe renal failure (eGFR \<30 mL/min) or renal replacement therapy
* Chronic total occlusion of a major coronary artery
* Left main stem stenosis ≥50% or left main stem equivalent (ostial left anterior descending and ostial circumflex stenosis ≥70%)
* In-stent restenosis
* Panned coronary, cerebrovascular, or peripheral arterial revascularization
* Planned cardiac or major surgery
* Any contraindications for dual antiplatelet therapy with aspirin …
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
The primary outcome measure is a composite of all-cause death, non-fatal myocardial infarction, unplanned ischemia-driven revascularization, hospitalization for heart failure, and stroke at 1 year